NXP800 in subjects with Ovarian Cancer
NXP800-101
Phase 1 other active
Quick answer
NXP800 in subjects with Ovarian Cancer for Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active